Trials / Unknown
UnknownNCT02133989
Clopidogrel Resistance and Embolism in Carotid Artery Stenting
Ticlopidine+Ginkgo Biloba Versus Clopidogrel in Clopidogrel Resistant Patients Undergoing Cartoid Artery Stent Placement
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 86 (estimated)
- Sponsor
- Samsung Medical Center · Academic / Other
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of the ticlopidine + ginko biloba compared to clopidogrel in clopidogrel resistant patients undergoing carotid artery stent placement. The investigators hypothesized that ticlopidine + ginko biloba is superior than clopidogrel in terms of post-stent ischemic lesions in these patients without serious complications.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ticlopidine + Ginko biloba | ticlopidine hydrochloride 250mg, ginko leaf ext. 80mg, twice daily |
| DRUG | Clopidogrel | clopidogrel bisulfate 97.875mg(75mg as clopidogrel) |
Timeline
- Start date
- 2014-06-01
- Primary completion
- 2017-12-01
- Completion
- 2017-12-01
- First posted
- 2014-05-08
- Last updated
- 2017-04-26
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT02133989. Inclusion in this directory is not an endorsement.